Literature DB >> 32709827

Retinal neovascularization in a patient with chronic central serous chorioretinopathy.

Vinod K Aggarwal1, Pulak Agarwal1, Shoryavardhan Azad1.   

Abstract

A 45-year-old male presented with diminution of vision in both eyes since the last 2 years. The best-corrected visual acuity was 20/200 in his right eye and 20/600 in left eye. BE fundi had changes of chronic CSCR with PED and NSD in the RE and subretinal fibrosis in the left eye. Both eyes had peripheral pigmentary changes. Multimodal imaging showed peripheral avascular retina in both eyes with neovascularization at disc in the right eye which promptly resolved with a single injection of anti-VEGF. Retinal neovascularization is an unusual finding in the setting of CSCR and has not been reported in the literature.

Entities:  

Keywords:  CSCR; NVD; pigmentary changes

Mesh:

Year:  2020        PMID: 32709827      PMCID: PMC7640812          DOI: 10.4103/ijo.IJO_2068_19

Source DB:  PubMed          Journal:  Indian J Ophthalmol        ISSN: 0301-4738            Impact factor:   1.848


  5 in total

1.  Vascular changes in rhegmatogenous retinal detachment.

Authors:  F Cardillo Piccolino
Journal:  Ophthalmologica       Date:  1983       Impact factor: 3.250

Review 2.  Central serous chorioretinopathy.

Authors:  Maria Wang; Inger Christine Munch; Pascal W Hasler; Christian Prünte; Michael Larsen
Journal:  Acta Ophthalmol       Date:  2007-07-28       Impact factor: 3.761

3.  Laser treatment of diffuse retinal pigment epitheliopathy.

Authors:  L A Yannuzzi; J S Slakter; S R Kaufman; K Gupta
Journal:  Eur J Ophthalmol       Date:  1992 Jul-Sep       Impact factor: 1.922

4.  Peripheral retinal avascularity and capillary leakage in central serous chorioretinopathy.

Authors:  V G Madanagopalan; Karan Shah; C K Nagesha; Prabu Baskaran
Journal:  J Curr Ophthalmol       Date:  2019-01-30

Review 5.  Management of chronic central serous chorioretinopathy.

Authors:  Daren Hanumunthadu; Anna C S Tan; Sumit Randhir Singh; Niroj Kumar Sahu; Jay Chhablani
Journal:  Indian J Ophthalmol       Date:  2018-12       Impact factor: 1.848

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.